Published Articles Sent to TSEAC Members for Their Review

for the  February 8, 2005 TSEAC meeting

 

  1. Removal of abnormal prion protein by plasma fractionation. Foster et al. Transfusion Sci. 22 (2000)53-56.
  2. variant Creutzfeldt Jakob Disease and Hemophilia - Further guidance on assessing the risks of plasma-derived products for treating hemophilia. Farrugia. WFH Task Force http://www.wfh.org/Content_Documents/Blood_Safety/WFH-TSE_Risk_Assessment2004.pdf
  3. Eurosurveillance Weekly archives 2004 > Vol 8 / Issue 39: vCJD and plasma products. http://www.eurosurveillance.org/ew/2004/040923.asp
  4. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Gregori L et al.  The Lancet 364 Aug 7, 2004 pp529-531.
  5. Risk Assessment of Exposure to vCJD Infectivity in Blood and Blood Products for Dept. Health. Det Norske Veritas. February 2003. http://www.dnv.com/consulting/news_consulting/riskofinfectionfromvariantcjdinblood.asp
  6. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Gregori L et al. Biologicals 32 (2004) 1-10
  7. vCJD and Blood Products. SCIEH Online - Healthcare Associated Infection - vCJD and Blood Products. http://www.show.scot.nhs.uk/scieh/ 
  8. Chart of 7th September 2004 vCJD and Plasma Products: Who my be Afffected,

http://www.hpa.org.uk/infections/topics_az/cjd/blood_products.htm

  1. Variant Creutzfeldt-Jakob Disease and Plasma Products: Information for Patients,

 http://www.hpa.org.uk/infections/topics_az/cjd/blood_products.htm

  1. Attributable testing for abnormal prion protein, database linkage, and blood –borne vCJD risks. S.M. Bird, Lancet 2004:1362-64.